Dermatol. praxi. 2018;12(4):164-166 | DOI: 10.36290/der.2018.041

Local therapy of inflammatory (papulopustular) lesions of rosacea in adult patients

MUDr. Radana Dwayebová
Kožní oddělení Nemocnice Nový Jičín, a. s., člen skupiny Agel

Papulopustular rosacea is a moderately severe form of facial dermatitis. It is characterized by the development of papules andpapulopustules on a permanently reddened skin. Cutaneous manifestations are situated in the central part of the face. There areseveral pathophysiological models of rosacea. Local therapy involves a number of external drugs aimed at relieving inflammatorysymptoms. Recently, ivermectin 1% cream has become the drug of choice in this subtype of rosacea, with its anti-inflammatoryand antiparasitic effects being utilized as well. Because of the simultaneous presence of persistent erythema, a recommendedcombination of ivermectin with the alpha-2 adrenergic receptor antagonist brimonidine is used that alleviates erythema by vasoconstrictionof cutaneous blood vessels. An integral part of the treatment is patient education on appropriate skin cosmetics,risk factors, and the need for photoprotection. Psychosomatic approach also plays an important role.

Keywords: papulopustular rosacea, local therapy, ivermectin, brimonidine

Received: February 25, 2019; Accepted: March 25, 2019; Prepublished online: March 25, 2019; Published: December 1, 2018  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Dwayebová R. Local therapy of inflammatory (papulopustular) lesions of rosacea in adult patients. Dermatol. praxi. 2018;12(4):164-166. doi: 10.36290/der.2018.041.
Download citation

References

  1. Rulcová J. Rosacea. In: Nevoralová Z, Rulcová J, Benáková N. Obličejové dermatózy. Mladá Fronta, a. s., Praha, 2016: 91-120.
  2. Štork J. Rosacea. In: Štork J. et al., Dermatovenerologie, druhé vydání, Praha: Galén 2013; 294-295.
  3. Pánková R. Rosacea, Dermatol.praxi 2017; 11(1): 6-11. Go to original source...
  4. Rulcová J. Přehled nejčastějších obličejových dermatóz. I. část. Dermatol.praxi 2014; 8(3): 98-101.
  5. Rulcová J. Kožní choroby postihující obličej. Referátový výběr z dermatovenerologie 2011; 35(III/speciál); 6-14.
  6. Wilkin J, Dahl M, Detmar M, Drake L, Feinstein A, Odom R et al. Standart classification of rosacea: Report of the National Rosacea Society Expert Committee on the Classification and Staging of Rosacea. J Am Acad Dermatol 2002; 46(4): 584-587. Go to original source... Go to PubMed...
  7. Nevoralová Z. Závažná forma růžovky u 32leté pacientky. Dermatol.praxi 2015; 9(3): 130-133.
  8. Casas C, Paul C, Lahfa M et al., Quantification of Demodex folliculorum by PCR in Rosacea and its relationship to skin innate immune activation. Exp.Dermatol. 2012; 21(12): 906-910. Www.:https://doi.org/10.111/exd.12030 Go to original source... Go to PubMed...
  9. Taieb A, Ortonne J P, Ruzicka T et al.: Ivermectin Phase III Study group. Superiority of ivermectin 1% cream over metronidazole 0,75% cream in treating inflammatory lesions of rosacea: a randomized, investigator-blinded trial; Br.J Dermatol 2015; 172, 1103-1110. Www.: https://doi.org/10.1111/bjd.13408 Go to original source... Go to PubMed...
  10. Presentation title: Concurrent Administration of Ivermectin 1% cream With Brimonidin 0,33% Gel Improves Efficacy and Tolerability in the Treatment of Moderate to Severe Rosacea. Abstract 7552. Www:https://jofskin.org/index.php/skin/article/view/147/128
  11. Gold L S, Papp K, Lynde C, Lain E, Drugs J : Treatment of Rosacea With Concomitant Use of Topical Ivermectin 1% Cream and Brimonidine 0,33% Gel: A Randomized, Vehicle-controlled Study, Dermatol. 2017, 16(9): 909-1616. Www:htpp://jddonline.com/artickles/dermatology/S1545961617P0909X/1
  12. https://www.galderma.cz/wp-content/uploads/2016/05/CZ_SPC_mirvaso_01-2017.pdf




Dermatology for Practice

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.